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Abstract— Treatment of cancer cachexia remains an unmet need. The host-tumour
interface and the resulting sequestration of the pro-inflammatory cytokine Il-1β is critical
in cachexia development. Neuroinflammation mediated via IL-1β through the hypothalamic
pituitary axis results in increased muscle proteolysis and adipose lipolysis, thus creating a
prolonged stress-like environment with loss of appetite and increased resting energy expen-
diture. Recent trials using a monoclonal antibody targeting IL-1β, canakinumab, have shown
a potential role in lung cancer; however, a potential role of targeting IL-1β to treat cachexia in
patients with lung cancer is unclear, yet the underlying pathophysiology provides a sound
rationale that this may be a viable therapeutic approach.
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INTRODUCTION
Conservative estimates suggest cancer cachexia is
attributable to over half of the cancer deaths worldwide
[1]. Yet despite its prevalence, adverse impact on quality of
life [2], and efficacy of anti-cancer therapy [3], there re-
mains no standard of care and no licenced therapy [4]. To
date, there has been a failure to progress the research
agenda in cancer cachexia and recently tested novel thera-
pies studies have failed to meet trial endpoints and thus
regulatory approval [5, 6].
The starting point for much of the work in the last
decade has been the international consensus publication of
2011 [7]. In this, cancer cachexia was defined as “a multi-
factorial syndrome defined by an ongoing loss of skeletal
muscle mass (with or without loss of fat mass) that cannot
be fully reversed by conventional nutritional support and
leads to progressive functional impairment. The pathophys-
iology is characterised by a negative protein and energy
balance driven by a variable combination of reduced food
intake and abnormal metabolism.” This definition acknowl-
edged the role of the systemic inflammatory response in
cachexia and this has been supported in the intervening
years by work showing the importance of systemic inflam-
matory responses in the progressive nutritional and func-
tional decline of patients with cancer; indeed, the systemic
inflammatory response can be regarded as a central tenet of
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cancer cachexia [4, 8–10]. Indeed, the European Society for
Clinical Nutrition and Metabolism (ESPEN) suggest that
cancer cachexia is synonymous with disease-related malnu-
trition in combination with inflammation [11, 12].
With reference to previous randomized trials in
cachexia, few have characterized the systemic inflam-
matory response as an entry criterion or as a therapeutic
target [5, 6, 13]. In contrast, there are increasing num-
bers of oncological trials incorporating measures of the
systemic inflammatory response as stratification vari-
ables [14]. Indeed the presence of the systemic inflam-
matory response has been firmly established as being
associated with weight loss and loss of lean mass [15–
17], reduced functional status [18, 19], anorexia [20,
21], quality of life [2, 18, 22–24], and reduced survival
[19, 25, 26].
It therefore follows that, with the systemic in-
flammatory response playing a key role in the devel-
opment of cachexia, there is a need to target this
response. Yet, to date, few studies have investigated
anti-inflammatory treatment in patients with cancer
cachexia [4, 9, 10].
INFLAMMATION AND CANCER CACHEXIA
The cancer-associated systemic inflammatory re-
sponse is recognized to be mediated by a network of
inflammatory cytokines, eicosanoids, and other factors
as part the tumour-host response. In patients with ad-
vanced cancer, pro-inflammatory cytokines predominate
leading to an upregulation of Interleukin 1 (IL-1) and
increased downstream production of IL-6 [27–31].
Therefore, downregulation of IL-1 is a logical therapeu-
tic target for moderation of the systemic inflammatory
response. Indeed, IL-1 inhibitors are established in the
treatment of inflammatory joint disease.
Role of IL-1 in Cachexia
In cachexia, the IL-1 pathway is overactive and con-
tributes to cachexia via several mechanisms [32]. It influ-
ences tryptophan secretion resulting in increased concen-
trations and subsequently excess hypothalamic derived
serotonin, causing satiety, and appetite suppression [33].
Whilst the actions of these cells normally represent an
acute physiological response to stress, they are exacerbated
by cancer where an inflammatory environment causes
prolonged stress, resulting in overstimulation causing mus-
cle wasting [9]. The impact of IL-1 on this mechanism has
been demonstrated by pre-clinical models in which IL-1
triggered the release of α-melanocyte stimulating hormone
(α-MSH) from pro-opiomelanocortin (POMC) neurones.
Then, α-MSH stimulates Melanocortin-4 (MC4-R)
neurones to induce appetite suppression [34]. Furthermore,
IL-1 exhibits an inhibitory effect on Neuropeptide Y
(NPY) neurones which also physiologically inhibits
MC4-R neurones [35, 36].
Studies have also shown that IL-1 stimulates hy-
pothalamic neurones which release corticotrophin re-
leasing hormone (CRH) [37]. This causes secretion of
adrenocorticotropic hormone and cortisol, which may
in turn mediate the catabolic effects of cachexia. This
link between IL-1, the hypothalamic pituitary axis
(HPA) and muscle wasting was explored further by in
a study by Braun et al. where inflammation was in-
duced in mouse models via intracerebroventricular in-
jections of IL-1 [38]. The mice exhibited an increase in
muscle-specific E3 ubiquitin ligases, a key requirement
for the catabolism of muscle. The same result was then
also achieved when inflammation was induced periph-
erally with LPS. Interestingly however, this study
showed that muscle catabolism was ameliorated in
mice which had undergone an adrenalectomy. Such
results infer that activation of the HPA axis is central
to the catabolic effects of IL-1.
Two IL-1 genes, IL1A and IL1B, encode IL-1α and
IL-1β and binding of either IL-1α or IL-1β to the IL-1R1
receptor. Although similarities exist between IL-1α and β,
clear differences are also present with the latter having a
greater pro-inflammatory effect, influencing carcinogene-
sis and invasiveness of cells [39]. The potential role of Il-
1α has been recently reviewed [40].
Role of IL-1β in Cancer
IL-1β is produced in response to inflammation by
monocytes, macrophages, and neutrophils and induces
production of stimulation of IL-6 [41]. IL-1β is released
from macrophages and along with its potent inflammatory
effect it has been widely established that IL-1β production
is upregulated in ovarian, lung, and GI cancers and in
general these cancers are associated with bad prognoses
[42]. IL-1β gene is located on chromosome 2q14 within a
360-kb region and it has been shown that key polymor-
phisms, IL-1beta +3954, are a risk factor for the develop-
ment of cachexia in patients with gastrointestinal cancers
[42]. This finding has been supported by other work dem-
onstrating the central role of IL-1β in cachexia [43–46].
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Role of IL-1β in Cachexia
IL-1β also plays a role cachexia development
through the CNS. Stimulated via peripheral inflamma-
tion, central inflammation (specifically the hypothala-
mus) results in release of multiple inflammatory factors
and alteration in neural mechanisms that result in pro-
teolysis and lipolysis. Further, this HPA-mediated ab-
normal regulation causes muscle breakdown with the
resulting supply of amino acid precursors for superflu-
ous hepatic gluconeogenesis. The resulting dysregula-
tion of POMC and AGRP [47], both of which control
lean muscle proteolysis and adipose lipolysis, and
MC4-R which regulates appetite and energy expendi-
ture [48] causes muscle wasting [9]. IL-1β has been
demonstrated as being a critical factor in this process
and thus a key player in the loss of lean mass, appetite,
and inflammatory upregulation, seen in cancer cachexia
[38, 43–46].
Targeting IL-1β in Cancer
It follows that as the pathophysiological mechanisms
of cancer cachexia are mediated by IL-1β, targeting this is
a logical approach. Canakinumab is a human monoclonal
antibody to IL-1β with a half-life of 26 days. Binding
directly to circulating IL-1β, it neutralizes activity between
IL-1β and its receptor, making it well suited to a therapeu-
tic role. Although this role has been established for over a
decade in rheumatological indications and other immuno-
logical diseases, it has recently been shown to efficacious
in prevention of cardiac disease, in comparison to placebo
(CANTOS trial) [49]. Of particular relevance was a subse-
quent analysis of the CANTOS cohort where the incidence
of lung malignancy was noted to be reduced in those
patients taking higher doses (150 mg or 300 mg) of
canakinumab [50]. This finding is perhaps not surprising
as the clear role of the inflammatory response in the devel-
opment of lung cancer is well established. It therefore
follows that attenuation of this targeting the potent pro-
inflammatory mediator IL-1β via canakinumab may yield
benefit. Ridker and co-workers also observed that the
beneficial effect was most likely in those with raised
CRP. Again, this observation echo’s recent work by Dolan
and co-workers highlighting the role of CRP in influencing
outcomes in clinical trials of anti-cancer therapies [14, 51].
The role of Canakinumab in the inflammatory process
in malignant disease is being examined; however, the
pathophysiological mechanisms are plausible. Currently,
the CANOPY suite of clinical trials in lung cancer is
underway and findings awaited with interest. However,
the potential role of canakinumab in the prevention or
treatment of cancer cachexia is unclear. Survival endpoints
are predominant in current trials and whilst quality of life
and other patient reported outcomes are examined, key
endpoints focussing on cancer cachexia are not within the
remit of the current trials.
Potential Role of Targeting IL-1β in Cancer Cachexia
Several studies further support the potential role of
canakinumab in the treatment of cancer cachexia. Djamil
and colleagues demonstrated that patients with cancer-
related anorexia had significantly higher levels of IL-1β
than comparators and that this was correlated with severity
of anorexia [52]. In patients with pancreatic cancer,
Fogelman and co-workers showed that IL-1β levels were
predictive of development of cancer cachexia and was
superior in this regard to other cytokines [53]. Another
prospective study demonstrated the superiority of IL-1β
over IL-6 in terms of correlation with the clinical pheno-
type of the cachexia syndrome [46].
Other work has echoed these findings further substan-
tiating the clear influence of IL-1β in cancer cachexia
genesis [54, 55].
CONCLUSION
IL-1β represents a cytokine involved in the patho-
physiology of cancer, with direct targeting a viable av-
enue to treat cancer cachexia as well as tumour load per
se. Work to date highlights the key role of IL-1β in the
central mechanisms of cancer cachexia supported by
emerging clinical trials. Yet to fully explore this, trials
are needed which include patients at risk of cancer
cachexia and that use endpoints sensitive enough to
examine the multiple clinical sequelae of cancer cachex-
ia. Further, cancer cachexia is a complex phenomenon
and targeting IL-1β in isolation may be insufficient but
combined with a background standard of cachexia care,
it may have its most optimal effect. Canakinumab has
been shown to have excellent tolerability in multiple
completed and ongoing clinical trials, as well as real
world experience [56]. The next logical step is to under-
take exploratory trials examining canakinumab with ro-
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